Toni-Maree Rogers, BMLS, Prudence A

Slides:

Advertisements

Similar presentations

Naomi Fujioka, MD, Christopher A. French, MD, Michael J

Advertisements

Characteristics and Outcomes of Small Cell Lung Cancer Patients Diagnosed During Two Lung Cancer Computed Tomographic Screening Programs in Heavy Smokers

ALK Protein Analysis by IHC Staining after Recent Regulatory Changes: A Comparison of Two Widely Used Approaches, Revision of the Literature, and a New.

Detection of ALK Gene Rearrangement in Non-small Cell Lung Cancer: A Comparison of Fluorescence In Situ Hybridization and Chromogenic In Situ Hybridization.

New Methods for ALK Status Diagnosis in Non–Small-Cell Lung Cancer: An Improved ALK Immunohistochemical Assay and a New, Brightfield, Dual ALK IHC–In.

Detection of Rearrangements and Transcriptional Up-Regulation of ALK in FFPE Lung Cancer Specimens Using a Novel, Sensitive, Quantitative Reverse Transcription.

Next-Generation Sequencing Identifies and Immunohistochemistry Confirms a Novel Crizotinib-Sensitive ALK Rearrangement in a Patient with Metastatic Non–Small-Cell.

ALK FISH and IHC: You Cannot Have One without the Other

Heterogeneity of Anaplastic Lymphoma Kinase Gene Rearrangement in Non–Small-Cell Lung Carcinomas: A Comparative Study Between Small Biopsy and Excision.

Jessica J. Lin, MD, Lauren L. Ritterhouse, MD, PhD, Siraj M

FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma Sandra Salvi, PhD, Serena Varesano, PhD, Simona Boccardo, PhD, Jean Louis.

Clinicopathologic Analysis of ROS1-Rearranged Non–Small-Cell Lung Cancer and Proposal of a Diagnostic Algorithm Heounjeong Go, MD, PhD, Dong-Wan Kim,

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib Trish Thorne-Nuzzo, BS, Crystal.

Increased ALK Gene Copy Number and Amplification are Frequent in Non-small Cell Lung Cancer Marta Salido, MSc, Lara Pijuan, MD, PhD, Luz Martínez-Avilés,

Electronic Updates for JTO Readers

MET and EGFR Mutations Identified in ALK-Rearranged Pulmonary Adenocarcinoma: Molecular Analysis of 25 ALK-Positive Cases Jennifer M. Boland, MD, Jin.

Bright-Field Dual-Color Chromogenic In Situ Hybridization for Diagnosing Echinoderm Microtubule-Associated Protein-Like 4-Anaplastic Lymphoma Kinase-Positive.

Interpretation of Anti-ALK Immunohistochemistry Results

High-Dose Crizotinib for Brain Metastases Refractory to Standard-Dose Crizotinib Young Hak Kim, MD, Hiroaki Ozasa, MD, Hiroki Nagai, MD, Yuichi Sakamori,

A Case of Large-Cell Neuroendocrine Carcinoma Harboring an EML4–ALK Rearrangement with Resistance to the ALK Inhibitor Crizotinib Naoki Omachi, MD, Shigeki.

A Long-Term Spinal Intramedullary Response to Ceritinib in ALK Rearranged Non– Small-Cell Lung Cancer Josette Biya, MD, Caroline Caramella, MD, Colin.

Comprehensive Hybrid Capture–Based Next-Generation Sequencing Identifies a Double ALK Gene Fusion in a Patient Previously Identified to Be False-Negative.

ALK and NRG1 Fusions Coexist in a Patient with Signet Ring Cell Lung Adenocarcinoma Lucia Anna Muscarella, PhD, Domenico Trombetta, PhD, Federico Pio.

A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib Akihiro Tamiya,

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Dual IHC and FISH Testing for ALK Gene Rearrangement in Lung Adenocarcinomas in a Routine Practice: A French Study Anne McLeer-Florin, PhD, Denis Moro-Sibilot,

Combined Use of ALK Immunohistochemistry and FISH for Optimal Detection of ALK- Rearranged Lung Adenocarcinomas Lynette M. Sholl, MD, Stanislawa Weremowicz,

ALK/EML4 Fusion Gene May Be Found in Pure Squamous Carcinoma of the Lung Anna Caliò, MD, Alessia Nottegar, MD, Eliana Gilioli, MD, Emilio Bria, MD, Sara.

A Sensitive ALK Immunohistochemistry Companion Diagnostic Test Identifies Patients Eligible for Treatment with Crizotinib Trish Thorne-Nuzzo, BS, Crystal.

Combinational Analysis of FISH and Immunohistochemistry Reveals Rare Genomic Events in ALK Fusion Patterns in NSCLC that Responds to Crizotinib Treatment

ALK Rearrangement Testing by FISH Analysis in Non–Small-Cell Lung Cancer Patients: Results of the First Italian External Quality Assurance Scheme Antonio.

Reliability Assurance of Detection of EML4-ALK Rearrangement in Non–Small Cell Lung Cancer: The Results of Proficiency Testing in China Yulong Li, MD,

ALK Rearrangement Detected in a Focus of Pulmonary Atypical Adenomatous Hyperplasia Filippo Lococo, MD, Alessandra Bisagni, MD, Maria Cecilia Mengoli,

Searching for ROS1 Rearrangements in Lung Cancer by Fluorescent In Situ Hybridization: The Importance of Probe Design Arnaud Uguen, MD, Pascale Marcorelles,

A Novel EML4-ALK Variant: Exon 6 of EML4 Fused to Exon 19 of ALK

Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients Joana Vidal, MD, Sergi Clavé, MSc, Silvia de Muga, PhD, Iria González,

Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer

Elizabeth B. Gottlin, PhD, Rex C. Bentley, MD, Michael J

Parallel FISH and Immunohistochemical Studies of ALK Status in 3244 Non–Small-Cell Lung Cancers Reveal Major Discordances Florian Cabillic, PharMD, PhD,

Detection of ALK Rearrangement by Immunohistochemistry in Lung Adenocarcinoma and the Identification of a Novel EML4-ALK Variant Ka-Fai To, MBChB, Joanna.

ALK Testing in Lung Adenocarcinoma: Technical Aspects to Improve FISH Evaluation in Daily Practice Vittoria Martin, PhD, Barbara Bernasconi, PhD, Elisabetta.

The Prognostic Significance of Focal Adhesion Kinase Expression in Stage I Non– Small-Cell Lung Cancer Grace K. Dy, MD, Lourdes Ylagan, MD, Saraswati.

Rapid and Dramatic Radiographic and Clinical Response to an ALK Inhibitor (Crizotinib, PF ) in an ALK Translocation-Positive Patient with Non-small.

Response to Crizotinib Observed in Lung Adenocarcinoma with MET Copy Number Gain but without a High-Level MET/CEP7 Ratio, MET Overexpression, or Exon.

Erratum Journal of Thoracic Oncology

A Different Method in Diagnosis of Multiple Primary Lung Cancer

Arnaud Uguen, MD, PhD Journal of Thoracic Oncology

A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib Yoon Jin Cha, MD, PhD, Byoung Chul.

High MET Receptor Expression But Not Gene Amplification in ALK 2p23 Rearrangement Positive Non–Small-Cell Lung Cancer Yan Feng, MD, Eugen C. Minca, MD,

Detection of ALK-Positive Non–Small-Cell Lung Cancers on Cytological Specimens: High Accuracy of Immunocytochemistry with the 5A4 Clone Spasenija Savic,

Mitotic Inhibitors Journal of Thoracic Oncology

Clinicopathologic Characteristics and Outcomes of Patients with Anaplastic Lymphoma Kinase-Positive Advanced Pulmonary Adenocarcinoma: Suggestion for.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Daniel B. Costa, MD, PhD, Susumu Kobayashi, MD, PhD

Lung Adenocarcinoma with Concurrent Exon 19 EGFR Mutation and ALK Rearrangement Responding to Erlotinib Sanjay Popat, MRCP, PhD, Alexandra Vieira de.

EML4-ALK Fusion Detected by RT-PCR Confers Similar Response to Crizotinib as Detected by FISH in Patients with Advanced Non-Small-Cell Lung Cancer Yan.

Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non–Small-Cell Lung Cancer Shengxiang Ren, MD, PhD, Fred.

A Novel Fusion of TPR and ALK in Lung Adenocarcinoma

Immunohistochemistry is a Reliable Screening Tool for Identification of ALK Rearrangement in Non–Small-Cell Lung Carcinoma and is Antibody Dependent

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Clinical Implications of Variant ALK FISH Rearrangement Patterns

Anaplastic Lymphoma Kinase Gene Rearrangements in Non-small Cell Lung Cancer are Associated with Prolonged Progression-Free Survival on Pemetrexed D.

European Lung Cancer Conference (ELCC) 2016 Organisation

IASLC 6th Latin American Conference on Lung Cancer

Christina S. Baik, MD, MPH, Marc C. Chamberlain, MD, Laura Q. Chow, MD

An International Interpretation Study Using the ALK IHC Antibody D5F3 and a Sensitive Detection Kit Demonstrates High Concordance between ALK IHC and.

A Dramatic Response to Crizotinib in a Non–Small-Cell Lung Cancer Patient with IHC- Positive and FISH-Negative ALK Jong-Mu Sun, MD, PhD, Yoon-La Choi,

ALK Status Testing in Non–Small-Cell Lung Carcinoma by FISH on ThinPrep Slides with Cytology Material Eugen C. Minca, MD, PhD, Christopher P. Lanigan,

ALK Gene Rearrangements: A New Therapeutic Target in a Molecularly Defined Subset of Non-small Cell Lung Cancer Benjamin Solomon, MBBS, PhD, Marileila.

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

Comparison of Methods in the Detection of ALK and ROS1 Rearrangements in Lung Cancer Toni-Maree Rogers, BMLS, Prudence A. Russell, FRCPA, Gavin Wright, FRACS, Zoe Wainer, BMBS, Jia-Min Pang, MBChB, Leigh A. Henricksen, PhD, Shalini Singh, MD, Stacey Stanislaw, BS, James Grille, BS, Esteban Roberts, PhD, Benjamin Solomon, PhD, Stephen B. Fox, DPhil Journal of Thoracic Oncology Volume 10, Issue 4, Pages 611-618 (April 2015) DOI: 10.1097/JTO.0000000000000465 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Comparison of staining intensities for three ALK antibodies of one sample (×10). A, DAKO ALK1 clone. B, Novocastra 5A4 clone. C, Cell Signaling Technology D5F3 clone. ALK, anaplastic lymphoma kinase. Journal of Thoracic Oncology 2015 10, 611-618DOI: (10.1097/JTO.0000000000000465) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 ALK signal patterns observed by FISH (×100) and dual-colour CISH (×63). A and B, A non-ALK-rearranged tumor. C and D An ALK-rearranged tumor with a split (greater than two signal widths apart). E and F, An ALK-rearranged tumor with an isolated 3′ end signal in conjunction with a fused signal. FISH, fluorescence in situ hybridization; CISH, chromogenic in situ hybridization; ALK, anaplastic lymphoma kinase. Journal of Thoracic Oncology 2015 10, 611-618DOI: (10.1097/JTO.0000000000000465) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 ROS1 signal patterns observed by FISH (×100) and dual-colour CISH (×63). A and B, A non-ROS1-rearranged tumor. C and D, A ROS1-rearranged tumor with a split (greater than two signal widths apart). E and F, A ROS1 signal pattern with an isolated 3′ end signal in conjunction with a fused signal. G and H, An atypical ROS1 signal pattern with an isolated 5′ end signal in conjunction with a fused signal. FISH, fluorescence in situ hybridization; CISH, chromogenic in situ hybridization. Journal of Thoracic Oncology 2015 10, 611-618DOI: (10.1097/JTO.0000000000000465) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions